Hims & Hers Health said it plans to begin selling peptides that are already legal to manufacture by the end of the year, including NAD+, sermorelin and glutathione, while waiting for final FDA rulemaking on other peptides under review for compounding. CEO Andrew Dudum told investors the company is developing a U.S.-manufactured offering, and Hims has begun stability and validation testing for BPC-157, a tissue-repair peptide being reviewed by regulators. Analysts and investors told Reuters that legally available peptides are unlikely to materially drive revenue growth this year because some products such as NAD+ are already widely available and demand appears stronger for peptides that could be newly permitted for compounding. The market for peptides has been estimated by analysts at $2.2 billion to $3.3 billion, but wider access still depends on the FDA after a nonbinding July advisory panel vote supporting compounding of six peptides despite staff concerns about limited evidence of safety and effectiveness. Hims, which owns a U.S. compounding pharmacy after acquiring a facility in 2025, is seen by some investors as well positioned to scale the business over time, though they do not expect growth to match the rapid rise of its GLP-1 weight-loss drug business.